LARS2

Across TCGA pan-cancer cohorts, LARS2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LARS2 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LARS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LARS2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

HNSC, KIRC, and UCEC are the cancer types where LARS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.155	0.685	.013	18	view →
KIRC	OS	Median	All	0.181	0.655	.046	6	view →
UCEC	DFS	Median	All	0.970	0.828	.024	6	view →
COAD	DFS	Median	All	0.160	0.693	.026	3	view →
STAD	DFS	Median	All	1.000	0.648	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LARS2–HNSC (OS)

Open the HNSC breakdown →